Jesús Fortún Abete-rekin lankidetzan egindako argitalpenak (20)

2023

  1. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

    The Lancet, Vol. 401, Núm. 10370, pp. 49-59

2022

  1. Erratum: Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies (Open Forum Infect Dis (2021) 8:6 DOI: 10.1093/ofid/ofab250)

    Open Forum Infectious Diseases

2021

  1. Early Stepdown from Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies

    Open Forum Infectious Diseases, Vol. 8, Núm. 6

2020

  1. An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 3, pp. 730-737

  2. Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child–Pugh B or C Liver Disease: A Case–Control Retrospective Study

    Infectious Diseases and Therapy, Vol. 9, Núm. 1, pp. 151-163

  3. Factors associated with the development of septic shock in patients with candidemia: A post hoc analysis from two prospective cohorts

    Critical Care, Vol. 24, Núm. 1

2019

  1. Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome

    Transplant Infectious Disease, Vol. 21, Núm. 6

  2. Usefulness of guideline recommendations for prognosis in patients with candidemia

    Medical mycology, Vol. 57, Núm. 6, pp. 659-667

2018

  1. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: A prospective pilot study

    Journal of Antimicrobial Chemotherapy, Vol. 73, pp. iv6-iv12

  2. T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study

    Journal of Antimicrobial Chemotherapy, Vol. 73, pp. iv13-iv19

2017

  1. Epidemiology and prognosis of candidaemia in elderly patients

    Mycoses, Vol. 60, Núm. 12, pp. 808-817

  2. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia

    Clinical Microbiology and Infection, Vol. 23, Núm. 1, pp. 49.e1-49.e8

  3. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance

    Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11

  4. Is routine ophthalmoscopy really necessary in candidemic patients?

    PLoS ONE, Vol. 12, Núm. 10

  5. No evidence of increased ocular involvement in candidemic patients initially treated with echinocandins

    Diagnostic Microbiology and Infectious Disease, Vol. 88, Núm. 2, pp. 141-144

2016

  1. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort

    Clinical Microbiology and Infection, Vol. 22, Núm. 8, pp. 733.e1-733.e8

2015

  1. A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains

    Clinical Microbiology and Infection, Vol. 21, Núm. 7, pp. 684.e1-684.e9

  2. Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance

    Journal of Infection, Vol. 71, Núm. 3, pp. 385-394

  3. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: RESULTS from a population-based surveillance in Spain

    Clinical Microbiology and Infection, Vol. 21, Núm. 5, pp. 491.e1-491.e10

2014

  1. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: A population-based surveillance in Spain

    Clinical Microbiology and Infection, Vol. 20, Núm. 4